Table 1. Route of administration and... | American Society of Hematology

Table 1.

Route of administration and standard dosing recommendations for approved complement inhibitors in adult patients with PNH

Drug	Target	Route	Loading dose	Maintenance dose	Frequency
Eculizumab	C5	Intravenous over 1 h	600 mg weekly ×4 doses; maintenance dosing starting week 5	900 mg	Every 2 wk
Ravulizumab	C5	Intravenous over 1 h	≥40 to <60 kg: 2400 mg ≥60 to <100 kg: 2700 mg ≥100 kg: 3000 mg; start maintenance dosing 2 wk later	≥40 to <60 kg: 3000 mg ≥60 to <100 kg: 3300 mg ≥100 kg: 3600 mg	Every 8 wk
Pegcetacoplan	C3	Subcutaneous infusion over 30-60 min	Overlap with C5 inhibitor for 4 wk	1080 mg	Twice weekly; every 3 d for LDH >2× ULN

Drug	Target	Route	Loading dose	Maintenance dose	Frequency
Eculizumab	C5	Intravenous over 1 h	600 mg weekly ×4 doses; maintenance dosing starting week 5	900 mg	Every 2 wk
Ravulizumab	C5	Intravenous over 1 h	≥40 to <60 kg: 2400 mg ≥60 to <100 kg: 2700 mg ≥100 kg: 3000 mg; start maintenance dosing 2 wk later	≥40 to <60 kg: 3000 mg ≥60 to <100 kg: 3300 mg ≥100 kg: 3600 mg	Every 8 wk
Pegcetacoplan	C3	Subcutaneous infusion over 30-60 min	Overlap with C5 inhibitor for 4 wk	1080 mg	Twice weekly; every 3 d for LDH >2× ULN